Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasm Metastasis × inavolisib × Clear all

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 4 Triple Negative Breast Neoplasms 2 Neoplasm, Residual 1 Neoplasm Metastasis 1 HER2-positive Breast Cancer 1 Endometrial Neoplasms 1

Interventions

Radiosurgery 74 Capecitabine 70 Oxaliplatin 63 Bevacizumab 62 Fluorouracil 61 Gemcitabine 56 Leucovorin 55 Nivolumab 49 pembrolizumab 46 Paclitaxel 41 Irinotecan 41 Radiotherapy 38 Cisplatin 35 Magnetic Resonance Spectroscopy 33 Everolimus 31 Cyclophosphamide 31 Cetuximab 31 Drug Therapy 30 Docetaxel 29 Ipilimumab 28 Carboplatin 27 Trastuzumab 25 Sorafenib 24 Sunitinib 23 Erlotinib Hydrochloride 20 Surveys and Questionnaires 19 Specimen Handling 18 Doxorubicin 18 Biopsy 18 Surgical Procedures, Operative 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

German Cancer Research Center

Phase 2 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡